# CoDa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coda-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.codatherapeutics.com
- Total disclosed funding: $62M
- Latest round: Series B (Jul 20, 2012)
- Investors on record: 4

## About

CoDa Therapeutics, Inc is a biotechnology company focused on developing innovative treatments for dermatological conditions, leveraging cutting-edge science to create effective therapeutic solutions.CoDa Therapeutics, Inc was founded in 2005 and is headquartered in San Diego, US. The company is dedicated to the advancement of therapeutic solutions for skin disorders. In June 2016, the firm raised USD 0.75 mn in Venture Debt financing. The company has successfully completed a total of 9 deals since its inception. Bradford Duft serves as the CEO of the company.CoDa Therapeutics specializes in developing advanced therapeutic solutions for dermatological conditions, focusing on enhancing patient outcomes through innovative treatments. Their product line is designed to address various skin disorders and improve the quality of life for patients through effective, targeted therapies that utilize proprietary technology and formulations.The company's revenue model is structured around direct sales of therapeutic products to healthcare providers and partnerships with pharmaceutical companies for distribution. This includes licensing agreements that enable further expansion of their product offerings. Their approach integrates both B2B relationships with health institutions and direct-to-consumer sales, ensuring a comprehensive market strategy that enhances revenue generation through diverse channels.CoDa Therapeutics plans to expand its product offerings by launching new dermatological treatments in the coming years, with specific timelines to be determined. The company aims to penetrate new geographic markets, particularly targeting Europe and Asia by 2025. The recent funding of USD 0.75 mn raised in June 2016 will be utilized to support these initiatives, enhancing their research and development capabilities to expedite product launches and market entry.

## Funding rounds

- Series B, Jul 20, 2012, $19M — Domain Associates, GBS Venture Partners, RMI Partners, BioPacific Partners
- Series B, Apr 14, 2011, $19M — Domain Associates, GBS Venture Partners, BioPacific Partners
- Series A, Sep 24, 2008, $8M — Domain Associates
- Series A, Feb 22, 2007, $10M — Domain Associates, GBS Venture Partners
- Series A, Oct 10, 2006, $5.6M — Domain Associates

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series A, Series B
- BioPacific Partners (https://capitalatlas.ai/funds/biopacific-partners) — Series B
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series B